Cite
HARVARD Citation
Wainberg, Z. et al. (2022). Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet oncology. 23 (11), pp. 1430-1440. [Online].